Symbols

Ionis Pharmaceuticals (IONS) Soars 17.32% on FDA Approval

Generated by AI AgentAinvest Pre-Market Radar

Tuesday, Sep 2, 2025 8:13 am ET1min read

Aime Summary

- Ionis Pharmaceuticals (IONS) jumped 17.32% pre-market after FDA approved its HAE drug, boosting revenue and market position.

- Piper Sandler raised its price target, reflecting confidence in the company's drug pipeline and regulatory progress.

- FDA's August 21 decision on Donidalorsen, an RNA-targeted therapy, could further impact stock performance and therapeutic potential.

Ionis Pharmaceuticals (IONS) surged 17.32% in pre-market trading on September 2, 2025, driven by significant developments in its drug pipeline and regulatory approvals.

Ionis Pharmaceuticals received FDA approval for its hereditary angioedema (HAE) drug, marking a major milestone for the company. This approval is expected to boost the company's revenue and market position. Additionally, Piper SandlerPIPR-- has lifted its target price for Ionis PharmaceuticalsIONS--, reflecting the positive outlook on the company's prospects.

Another key development is the FDA's decision on Donidalorsen, an investigational RNA-targeted medicine developed by Ionis Pharmaceuticals. The decision, expected on August 21, 2025, could further impact the company's stock performance. Donidalorsen is a promising drug that targets specific RNA sequences, offering potential therapeutic benefits for various diseases.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue